YaoGeJu

Company directoryChina company filings

Novast Laboratories, Limited

As of 17 November 2026, for the company name Novast Laboratories, Limited as recorded, 13 applications with this name as first applicant are listed as under review at China's CDE; the CDE acceptance records name it as first applicant on 30 records, across 19 drug names; since 21 August 2026, the records list Accepted: 1 application; the chemical-drug catalogue lists 16 active records with this name as holder.

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference

CDE data as of
2026/11/17
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/17.

Drug filings

30 acceptance records as first applicant, grouped into 19 source drug names. Source data as of 2026/11/17.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Ertugliflozin Tablets 1 records · Latest accepted 2026/11/05

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2602718Generic2026/11/05Novast Laboratories, LimitedCDE ↗
Trazodone Hydrochloride Sustained-release Tablets 1 records · Latest accepted 2026/05/20

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2601183Generic2026/05/20Novast Laboratories, LimitedCDE ↗
Linagliptin and Metformin Hydrochloride Extended Release Tablets 2 records · Latest accepted 2026/03/30

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2600746Generic2026/03/30Novast Laboratories, LimitedCDE ↗
CYHS2600745Generic2026/03/30Novast Laboratories, LimitedCDE ↗
Venlafaxine Hydrochloride Extended Release Tablets 1 records · Latest accepted 2026/02/26

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2600549Generic2026/02/26Novast Laboratories, LimitedCDE ↗
Estradiol Valerate Tablets 1 records · Latest accepted 2026/01/06

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2600064Generic2026/01/06Novast Laboratories, LimitedCDE ↗
Upadacitinib Sustained-release Tablets 1 records · Latest accepted 2026/01/04

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2600004Generic2026/01/04Novast Laboratories, LimitedCDE ↗
Finerenone Tablets 1 records · Latest accepted 2025/12/26

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2504451Generic2025/12/26Novast Laboratories, LimitedCDE ↗
炔雌醇环丙孕酮片 · No verified English name 1 records · Latest accepted 2025/12/02

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2504152Generic2025/12/02Novast Laboratories, LimitedCDE ↗
Metformin Hydrochloride And Empagliflozin Extended Release Tablets 4 records · Latest accepted 2025/01/07

Generic · 4

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2500085Generic2025/01/07Novast Laboratories, LimitedCDE ↗
CYHS2500084Generic2025/01/07Novast Laboratories, LimitedCDE ↗
CYHS2500083Generic2025/01/07Novast Laboratories, LimitedCDE ↗
CYHS2500082Generic2025/01/07Novast Laboratories, LimitedCDE ↗
美沙拉秦肠溶缓释胶囊 · No verified English name 1 records · Latest accepted 2025/01/07

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2500072Generic2025/01/07Novast Laboratories, LimitedCDE ↗
Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets (Ⅰ) 1 records · Latest accepted 2024/12/17

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2404362Generic2024/12/17Novast Laboratories, LimitedCDE ↗
Mesalazine Enteric-coated Tablets 1 records · Latest accepted 2024/12/05

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2404195Generic2024/12/05Novast Laboratories, LimitedCDE ↗
Sodium Valproate Sustained-release Tablets(I) 1 records · Latest accepted 2024/11/20

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2403975Generic2024/11/20Novast Laboratories, LimitedCDE ↗
Fluvastatin Sodium Extended Release Tablets 1 records · Latest accepted 2024/07/16

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2402188Generic2024/07/16Novast Laboratories, LimitedCDE ↗
Dienogest Tablets 1 records · Latest accepted 2023/07/10

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2301847Generic2023/07/10Novast Laboratories, LimitedCDE ↗
Sitagliptin and Metformin Hydrochloride Extended-release Tablets 3 records · Latest accepted 2023/04/24

Generic · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2301143Generic2023/04/24Novast Laboratories, LimitedCDE ↗
CYHS2301142Generic2023/04/24Novast Laboratories, LimitedCDE ↗
CYHS2301141Generic2023/04/24Novast Laboratories, LimitedCDE ↗
Metoprolol Succinate Sustained-release Tablets 2 records · Latest accepted 2023/03/01

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2300442Supplement2023/03/01Novast Laboratories, LimitedCDE ↗
CYHB2300135Supplement2023/01/17Novast Laboratories, LimitedCDE ↗
Drospirenone and Ethinylestradiol Tablets 2 records · Latest accepted 2022/03/04

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2200412Generic2022/03/04Novast Laboratories, LimitedCDE ↗
CYHS2200411Generic2022/03/04Novast Laboratories, LimitedCDE ↗
Memantine Hydrochloride Sustained-release Capsules 4 records · Latest accepted 2022/01/18

Generic · 4

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2200089Generic2022/01/18Novast Laboratories, LimitedCDE ↗
CYHS2200088Generic2022/01/18Novast Laboratories, LimitedCDE ↗
CYHS2200087Generic2022/01/18Novast Laboratories, LimitedCDE ↗
CYHS2200086Generic2022/01/18Novast Laboratories, LimitedCDE ↗

Changes in the last 90 days

1 events from 2026/08/21 to 2026/11/18. CDE data as of 2026/11/17; NMPA data as of 2026/11/17.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Accepted: 1 application

  1. 2026/11/05Accepted

    Ertugliflozin Tablets

    CYHS2602718

    Fact date: 2026/11/05 · Date added to this site: 2026/11/06

    View source ↗

Under review

13 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/17.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Ertugliflozin Tablets CYHS2602718Generic2026/11/05Novast Laboratories, LimitedCDE ↗
Trazodone Hydrochloride Sustained-release Tablets CYHS2601183Generic2026/05/20Novast Laboratories, LimitedCDE ↗
Linagliptin and Metformin Hydrochloride Extended Release Tablets CYHS2600746Generic2026/03/30Novast Laboratories, LimitedCDE ↗
Linagliptin and Metformin Hydrochloride Extended Release Tablets CYHS2600745Generic2026/03/30Novast Laboratories, LimitedCDE ↗
Venlafaxine Hydrochloride Extended Release Tablets CYHS2600549Generic2026/02/26Novast Laboratories, LimitedCDE ↗
Estradiol Valerate Tablets CYHS2600064Generic2026/01/06Novast Laboratories, LimitedCDE ↗
Upadacitinib Sustained-release Tablets CYHS2600004Generic2026/01/04Novast Laboratories, LimitedCDE ↗
Finerenone Tablets CYHS2504451Generic2025/12/26Novast Laboratories, LimitedCDE ↗
炔雌醇环丙孕酮片 · No verified English name CYHS2504152Generic2025/12/02Novast Laboratories, LimitedCDE ↗
Metformin Hydrochloride And Empagliflozin Extended Release Tablets CYHS2500085Generic2025/01/07Novast Laboratories, LimitedCDE ↗
Metformin Hydrochloride And Empagliflozin Extended Release Tablets CYHS2500084Generic2025/01/07Novast Laboratories, LimitedCDE ↗
Metformin Hydrochloride And Empagliflozin Extended Release Tablets CYHS2500083Generic2025/01/07Novast Laboratories, LimitedCDE ↗
Metformin Hydrochloride And Empagliflozin Extended Release Tablets CYHS2500082Generic2025/01/07Novast Laboratories, LimitedCDE ↗

Catalogue holder records

16 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/17. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Sodium Valproate Sustained-release Tablets(I)Novast Laboratories, LimitedNovast Laboratories, Limited国药准字H202656872026/08/25Generic approved under the new chemical-drug registration classificationCDE ↗
Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets (Ⅰ)Novast Laboratories, LimitedNovast Laboratories, Limited国药准字H202639232026/04/14Generic approved under the new chemical-drug registration classificationCDE ↗
Fluvastatin Sodium Extended Release TabletsNovast Laboratories, LimitedNovast Laboratories, Limited国药准字H202555622025/09/23Generic approved under the new chemical-drug registration classificationCDE ↗
Sitagliptin and Metformin Hydrochloride Extended-release TabletsNovast Laboratories, LimitedNovast Laboratories, Limited国药准字H202550562025/07/30Generic approved under the new chemical-drug registration classificationCDE ↗
西格列汀二甲双胍缓释片(II) · No verified English nameNovast Laboratories, LimitedNovast Laboratories, Limited国药准字H202550572025/07/30Generic approved under the new chemical-drug registration classificationCDE ↗
Sitagliptin and Metformin Hydrochloride Extended-release TabletsNovast Laboratories, LimitedNovast Laboratories, Limited国药准字H202550582025/07/30Generic approved under the new chemical-drug registration classificationCDE ↗
Dienogest TabletsNovast Laboratories, LimitedNovast Laboratories, Limited国药准字H202531032025/01/08Generic approved under the new chemical-drug registration classificationCDE ↗
Drospirenone and Ethinylestradiol TabletsNovast Laboratories, LimitedNovast Laboratories, Limited国药准字H202496202024/12/01Generic approved under the new chemical-drug registration classificationCDE ↗
Drospirenone and Ethinylestradiol TabletsNovast Laboratories, LimitedNovast Laboratories, Limited国药准字H202491922024/10/29Generic approved under the new chemical-drug registration classificationCDE ↗
Desogestrel and Ethinylestradiol TabletsNovast Laboratories, LimitedNovast Laboratories, Limited国药准字H202441382024/06/25Generic approved under the new chemical-drug registration classificationCDE ↗
Memantine Hydrochloride Sustained-release CapsulesNovast Laboratories, LimitedNovast Laboratories, Limited国药准字H202340762023/08/29Generic approved under the new chemical-drug registration classificationCDE ↗
Memantine Hydrochloride Sustained-release CapsulesNovast Laboratories, LimitedNovast Laboratories, Limited国药准字H202340792023/08/29Generic approved under the new chemical-drug registration classificationCDE ↗
Memantine Hydrochloride Sustained-release CapsulesNovast Laboratories, LimitedNovast Laboratories, Limited国药准字H202340782023/08/29Generic approved under the new chemical-drug registration classificationCDE ↗
Memantine Hydrochloride Sustained-release CapsulesNovast Laboratories, LimitedNovast Laboratories, Limited国药准字H202340772023/08/29Generic approved under the new chemical-drug registration classificationCDE ↗
Quetiapine Fumarate Extended-release TabletsNovast Laboratories, LimitedNovast Laboratories, Limited国药准字H202333942023/04/04Generic approved under the new chemical-drug registration classificationCDE ↗
Quetiapine Fumarate Extended-release TabletsNovast Laboratories, LimitedNovast Laboratories, Limited国药准字H202333952023/04/04Generic approved under the new chemical-drug registration classificationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/17.

NameCompany / applicantRegistration numberStatusSource update dateView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/17.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/17
Chemical-drug catalogue
Last successful update: 2026/11/17
API registrations
Last successful update: 2026/11/17
NMPA drug delivery notices
Last successful update: 2026/11/17

Loaded notices dated 2026-11-03 to 2026-11-17; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.